Dan Roden
Faculty Member
Last active: 3/24/2020

Cardiovascular pharmacogenomics: current status and future directions.

Roden DM
J Hum Genet. 2016 61 (1): 79-85

PMID: 26178435 · PMCID: PMC4849475 · DOI:10.1038/jhg.2015.78

Drugs are widely used and highly effective in the treatment of heart disease. Nevertheless, in some instances, even drugs effective in a population display lack of efficacy or adverse drug reactions in individual patients, often in an apparently unpredictable fashion. This review summarizes the genomic factors now known to influence variability in responses to widely used cardiovascular drugs such as clopidogrel, warfarin, heparin and statins. Genomic approaches being used to discover new pathways in common cardiovascular diseases and thus potential new targets for drug development are described. Finally, the way in which this new information is likely to be used in an electronic medical record environment is discussed.

MeSH Terms (12)

Arrhythmias, Cardiac Cardiovascular Agents Clopidogrel Genetic Variation Genomics Genomics Hematologic Agents Heparin Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacogenetics Ticlopidine Warfarin

Connections (1)

This publication is referenced by other Labnodes entities: